Cancer ‘vaccine’ eliminates tumors in mice,‘Amazing, bodywide effects’|part-2|
Cancer ‘vaccine’ eliminates tumors in mice,‘Amazing, bodywide effects’ Part 1:https://www.youtube.com/watch?v=Zvf6b3Xfjj8
Levy is a pioneer in the field of cancer immunotherapy, in which researchers try to harness the immune system to combat cancer. Research in his laboratory led to the development of rituximab, one of the first monoclonal antibodies approved for use as an anticancer treatment in humans.
Some immunotherapy approaches rely on stimulating the immune system throughout the body. Others target naturally occurring checkpoints that limit the anti-cancer activity of immune cells. Still others, like the CAR T-cell therapy recently approved to treat some types of leukemia and lymphomas, require a patient’s immune cells to be removed from the body and genetically engineered to attack the tumor cells. Many of these approaches have been successful, but they each have downsides — from difficult-to-handle side effects to high-cost and lengthy preparation or treatment times.
“All of these immunotherapy advances are changing medical practice,” Levy said. “Our approach uses a one-time application of very small amounts of two agents to stimulate the immune cells only within the tumor itself. In the mice, we saw amazing, bodywide effects, including the elimination of tumors all over the animal.”
Cancers often exist in a strange kind of limbo with regard to the immune system. Immune cells like T cells recognize the abnormal proteins often present on cancer cells and infiltrate to attack the tumor. However, as the tumor grows, it often devises ways to suppress the activity of the T cells.
Levy’s method works to reactivate the cancer-specific T cells by injecting microgram amounts of two agents directly into the tumor site. (A microgram is one-millionth of a gram). One, a short stretch of DNA called a CpG oligonucleotide, works with other nearby immune cells to amplify the expression of an activating receptor called OX40 on the surface of the T cells. The other, an antibody that binds to OX40, activates the T cells to lead the charge against the cancer cells. Because the two agents are injected directly into the tumor, only T cells that have infiltrated it are activated. In effect, these T cells are “prescreened” by the body to recognize only cancer-specific proteins.
About US :
IMPORTANT NOTE ABOUT VIDEO:- THE VIEWS AND OPINIONS EXPRESSED IN THE MEDIA OR COMMENTS ON THIS CHANNEL/IN THIS VIDEO ARE THOSE OF THE SPEAKERS OR AUTHORS AND DO NOT NECESSARILY REFLECT OR REPRESENT THE VIEWS AND OPINIONS HELD BY THIS CHANNEL'S BROADCASTER. THE IMAGES SOWN IN THIS NEWS IS MAY OR MAY NOT BE EXACTLY RELATED WITH THE NEWS SAID IN THIS VIDEO..ITS JUST FOR ILLUSTRATION PURPOSES...
WE are sharing News with we always respect the source should each video, written source of it. Over here, we have contributed to support the electronic page get backlink.
There is no copyright infringement intended for the video and/or material used in this video. If you have an issue with posting this, please contact us at ”firstname.lastname@example.org”
and we can sort it out. if you have any dispute/issue then msg us, we will reply you with in 24 hours..
Videos can use content-based copyright law contains reasonable use Fair Use .We Bring You All The Latest News & Politics.
References/Source/Credits (FAIR USE) : https://goo.gl/Bg4ny1
AUTHOR(WRITER): By researchers at the Stanford University School of Medicine.
Copyright Disclaimer: Citation of articles and authors in this report does not imply ownership. Works and images presented here fall under Fair Use Section 107 and are used for commentary on globally significant newsworthy events. Under Section 107 of the Copyright Act 1976, allowance is made for fair use for purposes such as criticism, comment, news reporting, teaching, scholarship, and research.
Do you have any query or need any support then Contact us at ”email@example.com”, we are happy to communicate with you, WE WILL REPLY TO YOU WITH IN 24 HOURS..Thanks Keep Your support always